Intradigm awarded US patent for RNAi enhancement methods
Intradigm Corp, a USA-based developer of targeted, systemic RNA interference therapeutics, has been awarded a US patent, entitled Methods and Compositions for Controlling Efficacy of RNA Silencing.
The issued patent generally claims methods of enhancing the RNA silencing activity of an RNAi agent through certain structural modifications in various cell types, including mammalian, the firm noted.
The claims not only focus on siRNA but also include specific ones directed to micro RNA, pre-miRNA, and short hairpin RNA. This patent issues from a portfolio of several applications disclosing efficacy-enhancing methods and structural elements of RNAi therapeutics that Intradigm has exclusively licensed from the University of Massachusetts Medical School, USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze